While this cell line is a valuable tool for studying aggressive and treatment-resistant phenotypes, it does not fully capture the heterogeneity of HER2-negative breast cancer, particularly hormone receptor-positive subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.